Allez plus loin
In this section, you will learn more about Gattefossé Pharmaceuticals expertise, through news, hot topics and publications at the cutting edge of science, you can browse through a library of on-demands webinars, and download our latest brochures.
Nouveautés et sujets d'actualité
Gattefossé Asia-Pacific is proud to host two scientific seminars in Tokyo and Osaka, on March 13th and March 14th. On this occasion, we partner with our local distributor, Shima, and have invited distinguished scientists, to offer to our clients detailed presentations on our products and latest innovations in Self-Emulsifying Drug Delivery Systems (SEDDS).
Every woman faces a gynecological disorder at some point in her life, during puberty, maternity, menopause or post menopause. These age periods structure the women’s health market with treatments for menopause related disorders, postmenopausal osteoporosis, infertility, endometriosis, gynecological cancer and birth control.
Pediatric patients have specific needs we have to take into account when developing formulations:
- need for dose flexibility to adapt to the body weight
- difficulty to swallow pills
- very sensitive to bitterness
- delicate skin
Focus on some solutions adapted to these specific challenges.
Nos dernières publications
Establishment of a continuous inline-monitored nano-production line using the Microfluidizer® technology for the fabrication of safe lipid-based nanoparticles
Nano-drug delivery systems (NDDS) serve as a promising platform in modern medicine, facilitating the targeted delivery of drugs due to their versatile size, structure, and composition. However, the current industrial production of NDDS relies on cumbersome batch processes that are costly, difficult to scale, and lack adequate control. This study focuses on enhancing industrial-scale production through the development and testing of a continuous top-down production line, utilizing scalable Microfluidizer® technology for solvent-free preparation of lipid-based nanoparticles.
In vivo confirmation of the permeation enhancement capacity of Labrafac™ MC60